News | Mammography | April 04, 2017

Five-year study employed Kubtec’s Mozart System with TomoSpec technology

digital breast tomosynthesis, DBT, 3-D mammography, breast imaging, re-excision rate, breast surgeries, ECR 2017, Kubtec Mozart System

April 4, 2017 — A study presented at the 2017 European Congress of Radiology (ECR) has concluded that adding digital breast tomosynthesis (DBT) is emerging as promising technology for surgical planning, as it offers a better view of lesion margins than mammography alone. The study results were presented at ECR 2017, March 1-5 in Vienna, Austria, by Alessia Milan, Ph.D., from the University of Turin.

The five-year study of 925 breast cancer patients demonstrated that the use of DBT can reduce re-excision rates by up to 50 percent.

"Margin status is one of the most important predictors for local recurrence following breast cancer surgery, and accurate pre-operative staging helps to plan appropriate surgical treatment and reduce the consequences of re-excision," Milan told meeting attendees. "These consequences can include emotional burden for the patient, a worse cosmetic outcome and higher costs."

The latest tool to use digital tomosynthesis to drive a reduction in positive margins is the Mozart System with TomoSpec Technology from Kubtec. The company said it is the first and only 3-D specimen tomosynthesis system designed specifically for intraoperative use.

Rather than producing a single 2-D planar view of multiple tissue layers, the Mozart System uses 3-D tomosynthesis technology to eliminate tissue interference by digitally removing overlying or underlying tissue in 1mm slices. This means that potential extensions of the cancer, radiating laterally or deep to the lesion, can be seen with greater clarity, helping to decrease the risk of positive margins and optimizing the cosmetic outcome of the procedure.

The Mozart System uses digital tomosynthesis to provide a three-dimensional solution to a three-dimensional problem during the treatment stage of breast cancer.

For more information: www.kubtec.com


Additional Content

News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | Radiopharmaceuticals and Tracers

Oct. 19, 2026 — Nuclidium AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, a global ...

Time October 19, 2026
arrow
News | Women's Health

Oct. 15, 2026— SimBioSys has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of TumorSight Risk, its ...

Time October 19, 2026
arrow
News | Breast Imaging

Oct. 6, 2026 — The American College of Radiology (ACR) has recognized Mercy Medical Center’s Tyanna O’Brien Center for ...

Time October 09, 2026
arrow
News | Artificial Intelligence

Sept. 29, 2026 — A recently published study shows that using artificial intelligence to track which pathologies ...

Time October 01, 2026
arrow
Subscribe Now